Pluristem Therapeutics Selected to Present Data from Phase II IC Study at the American Heart Association Scientific Sessions
October 18 2018 - 6:30AM
The Company will also present at the
BioEurope, Annual Vascular Interventional Advances and Cell and
Gene Therapy Manufacturing conferences, all held in
November
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading
regenerative medicine company developing novel placenta-based cell
therapy products, today announced that the Company will be
presenting at four conferences during November: at the BioEurope
conference, which is being held November 5–7, 2018 in Copenhagen,
at the 15th Annual Vascular Interventional Advances (VIVA)
Conference, which is being held November 5-8 in Las Vegas, at the
2018 American Heart Association (AHA) Scientific Sessions, which
are being held November 10-12 in Chicago and the Cell and Gene
Therapy Manufacturing conference, which is being held November
14-15 in London.
At the AHA Scientific Sessions, Prof. Norbert
Wiess, the Principal Investigator of the Company’s Phase II
intermittent claudication (IC) study, will present detailed results
from the study. The presentation will be held on Saturday, November
10, 2018 from 9:00-10:15am. In June 2018, the Company announced
positive top-line results from its multinational Phase II clinical
study of PLX-PAD cells in the treatment of IC. Data demonstrated
PLX-PAD’s ability to reduce the incidence of revascularization and
improved patients’ mobility. Study results also validate the design
of Pluristem’s ongoing pivotal Phase III study in critical limb
ischemia (CLI), a more severe stage of PAD.
At the VIVA Conference, during the Disruptive
Technology session, Pluristem will present an overview of its
off-the-shelf, placenta-derived cell therapy technology and
development plans for its lead cell therapy candidate, PLX-PAD, for
the treatment of peripheral artery disease (PAD). The presentation
will be held on Wednesday, November 7, 2018 from 8:15-9:15am.
At the BioEurope conference, during the cell and
gene track, Pluristem will present an overview of its cell therapy
products and clinical development. The presentation will be held on
Tuesday, November 6, 2018, from 10:00-11:00am.
At the Cell and Gene Therapy Manufacturing
conference, Pluristem will present an overview of its in-house
manufacturing process. The presentation will be held on Thursday,
November 15, 2018 from 9:10-9:50am.
About Pluristem
TherapeuticsPluristem Therapeutics Inc. is a leading
regenerative medicine company developing novel placenta-based cell
therapy products. The Company has reported robust clinical trial
data in multiple indications for its patented PLX cells and is
entering late stage trials in several indications. PLX cell
products release a range of therapeutic proteins in response to
inflammation, ischemia, muscle trauma, hematological disorders, and
radiation damage. The cells are grown using the Company's
proprietary three-dimensional expansion technology and can be
administered to patients off-the-shelf, without tissue matching.
Pluristem has a strong intellectual property position;
Company-owned and operated, GMP-certified manufacturing and
research facilities; strategic relationships with major research
institutions; and a seasoned management team.
Safe Harbor Statement
This press release contains express or implied
forward-looking statements within the Private Securities Litigation
Reform Act of 1995 and other U.S. Federal securities laws. For
example, Pluristem is using forward-looking statements when it
discusses the timing, description and results of its clinical
studies and its belief that the PLX-PAD study results validate the
design of its ongoing Phase III study in CLI. These forward-looking
statements and their implications are based on the current
expectations of the management of Pluristem only, and are subject
to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the
forward-looking statements. The following factors, among others,
could cause actual results to differ materially from those
described in the forward-looking statements: changes in technology
and market requirements; Pluristem may encounter delays or
obstacles in launching and/or successfully completing its clinical
trials; Pluristem’s products may not be approved by regulatory
agencies, Pluristem’s technology may not be validated as it
progresses further and its methods may not be accepted by the
scientific community; Pluristem may be unable to retain or attract
key employees whose knowledge is essential to the development of
its products; unforeseen scientific difficulties may develop with
Pluristem’s process; Pluristem’s products may wind up being more
expensive than it anticipates; results in the laboratory may not
translate to equally good results in real clinical settings;
results of preclinical studies may not correlate with the results
of human clinical trials; Pluristem’s patents may not be
sufficient; Pluristem’s products may harm recipients; changes in
legislation may adversely impact Pluristem; inability to timely
develop and introduce new technologies, products and applications;
loss of market share and pressure on pricing resulting from
competition, which could cause the actual results or performance of
Pluristem to differ materially from those contemplated in such
forward-looking statements. Except as otherwise required by law,
Pluristem undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. For a more detailed description of the risks
and uncertainties affecting Pluristem, reference is made to
Pluristem's reports filed from time to time with the Securities and
Exchange Commission.
Contact:
Efrat KaduriHead of Investor and Public
Relations972-74-7108600efratk@pluristem.com
Karine Kleinhaus, MD, MPHDivisional VP, North
America1-914-512-4109karinek@pluristem.com
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Apr 2023 to Apr 2024